全文获取类型
收费全文 | 1835191篇 |
免费 | 133285篇 |
国内免费 | 2781篇 |
专业分类
耳鼻咽喉 | 24130篇 |
儿科学 | 60424篇 |
妇产科学 | 49420篇 |
基础医学 | 276156篇 |
口腔科学 | 51622篇 |
临床医学 | 169093篇 |
内科学 | 354057篇 |
皮肤病学 | 40640篇 |
神经病学 | 141711篇 |
特种医学 | 67868篇 |
外国民族医学 | 335篇 |
外科学 | 264276篇 |
综合类 | 38495篇 |
现状与发展 | 4篇 |
一般理论 | 692篇 |
预防医学 | 146627篇 |
眼科学 | 41830篇 |
药学 | 136695篇 |
9篇 | |
中国医学 | 4150篇 |
肿瘤学 | 103023篇 |
出版年
2018年 | 19683篇 |
2017年 | 15106篇 |
2016年 | 16588篇 |
2015年 | 19028篇 |
2014年 | 26154篇 |
2013年 | 39884篇 |
2012年 | 53662篇 |
2011年 | 56982篇 |
2010年 | 33216篇 |
2009年 | 31792篇 |
2008年 | 53656篇 |
2007年 | 57460篇 |
2006年 | 57456篇 |
2005年 | 55447篇 |
2004年 | 53549篇 |
2003年 | 51176篇 |
2002年 | 49600篇 |
2001年 | 84563篇 |
2000年 | 86174篇 |
1999年 | 72169篇 |
1998年 | 19869篇 |
1997年 | 17614篇 |
1996年 | 18173篇 |
1995年 | 17267篇 |
1994年 | 16047篇 |
1993年 | 14942篇 |
1992年 | 56703篇 |
1991年 | 56090篇 |
1990年 | 54351篇 |
1989年 | 53124篇 |
1988年 | 49015篇 |
1987年 | 47840篇 |
1986年 | 45619篇 |
1985年 | 42956篇 |
1984年 | 32468篇 |
1983年 | 28030篇 |
1982年 | 16217篇 |
1981年 | 14652篇 |
1979年 | 30411篇 |
1978年 | 22030篇 |
1977年 | 18478篇 |
1976年 | 17402篇 |
1975年 | 18885篇 |
1974年 | 22617篇 |
1973年 | 22193篇 |
1972年 | 20888篇 |
1971年 | 19590篇 |
1970年 | 18620篇 |
1969年 | 17415篇 |
1968年 | 16158篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
Koel Dutt P N Agarwal Rajdeep Singh Vikas Singh Tomar 《The Indian journal of surgery》2015,77(1):62-64
Haemophilia is a common cause of genetically inherited bleeding disorders. Pseudotumours occur in 1–2 % of persons with severe forms of haemophilia. These are a result of repeated haemorrhage into soft tissues, subperiosteum or a site of bone fracture with inadequate resorption of the extravasated blood. There are a number of therapeutic alternatives for this dangerous condition: surgical removal, percutaneous management, irradiation, embolization etc. In this case report, we describe the natural history, clinical course and successful surgical management of a patient with haemophilia who presented with a massive pseudotumour. We also briefly review the relevant literature on the various therapeutic modalities that have been implemented in the management of this rare complication. Though surgeons may be averse to operate on haemophiliacs, primary surgical management as done in our case may prove to be the definitive treatment option for such patients. 相似文献
13.
As millions of people turn to social media for health information, better understanding the factors that guide health-related judgments and perceptions in this context is imperative. We report on two Web experiments (n > 400 total) examining the power of society’s widespread weight bias and related stereotypes to influence nutrition judgments in social media spaces. In Experiment 1, meals were judged as lower in nutritional quality when the person who recommended them (the source) was depicted as obese rather than of normal weight, an effect mediated by stereotypic beliefs about the source as a generally unhealthy person. Experiment 2 replicated this effect, which—notably—remained significant when controlling for objective nutritional information (calories and fat content). Results highlight spillover effects of weight bias that extend beyond person perception to color impressions of objects (here, food) that are associated with stigmatized attributes. Implications for everyday nutrition judgments and public health are considered. 相似文献
14.
15.
16.
17.
18.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
19.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
20.